B-lymphocytes from a population of children with autism spectrum disorder and their unaffected siblings exhibit hypersensitivity to thimerosal
- PMID: 23843785
- PMCID: PMC3697751
- DOI: 10.1155/2013/801517
B-lymphocytes from a population of children with autism spectrum disorder and their unaffected siblings exhibit hypersensitivity to thimerosal
Abstract
The role of thimerosal containing vaccines in the development of autism spectrum disorder (ASD) has been an area of intense debate, as has the presence of mercury dental amalgams and fish ingestion by pregnant mothers. We studied the effects of thimerosal on cell proliferation and mitochondrial function from B-lymphocytes taken from individuals with autism, their nonautistic twins, and their nontwin siblings. Eleven families were examined and compared to matched controls. B-cells were grown with increasing levels of thimerosal, and various assays (LDH, XTT, DCFH, etc.) were performed to examine the effects on cellular proliferation and mitochondrial function. A subpopulation of eight individuals (4 ASD, 2 twins, and 2 siblings) from four of the families showed thimerosal hypersensitivity, whereas none of the control individuals displayed this response. The thimerosal concentration required to inhibit cell proliferation in these individuals was only 40% of controls. Cells hypersensitive to thimerosal also had higher levels of oxidative stress markers, protein carbonyls, and oxidant generation. This suggests certain individuals with a mild mitochondrial defect may be highly susceptible to mitochondrial specific toxins like the vaccine preservative thimerosal.
Figures
References
-
- Prevention CfDa., editor. CDC. Autism Spectrum Disorders (ASDs) in: C.f.D.C.a. Prevention, (Ed.), US Government, 2012.
-
- CDC. Prevalence of autism spectrum disorders—autism and developmental disabilities monitoring network, 14 sites, United States, 2002. MMWR. Surveillance Summaries: Morbidity and Mortality Weekly Report. Surveillance Summaries. 2007;56:12–28. - PubMed
-
- Knapp M, Romeo R, Beecham J. Economic cost of autism in the UK. Autism. 2009;13(3):317–336. - PubMed
-
- Ganz ML. The lifetime distribution of the incremental societal costs of autism. Archives of Pediatrics and Adolescent Medicine. 2007;161(4):343–349. - PubMed
-
- Shimabukuro TT, Grosse SD, Rice C. Medical expenditures for children with an autism spectrum disorder in a privately insured population. Journal of Autism and Developmental Disorders. 2008;38(3):546–552. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
